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Although recognition of asthma as a disease goes
back at least to Hippocrates, to whom we owe the
name, effective treatments for asthma have only
been available since the middle of the twentieth
century, when it became clear that sympathomimetic
drugs could alleviate asthma symptoms and that
glucocorticosteroids could diminish the frequency of
attacks. Modern treatment rests on the use of airway-
selective b-agonists such as salbutamol, developed
in the 1960s, for immediate symptom relief and
inhaled corticosteroids and long-acting b-agonists,
developed in the 1990s, as controller therapy to
prevent attacks. From a public health perspective,
however, the existence of effective treatments is
not sufﬁcient. It is also important that they be
available to the patients who most need them
and that they be used appropriately as part of
a comprehensive approach to asthma management.
This approach involves risk prevention measures,
individualised treatment strategies, exacerbation
management plans and appropriate monitoring.
Collecting data on the prevalence and burden of
asthma, on the quality of care and on physician
and patient attitudes to asthma is critical for
national and regional healthcare providers to mould
public health policies and to allocate appropriate
resources to comprehensive asthma management
in their territories. It is in this perspective that
Glaxo Wellcome Laboratories (now GlaxoSmithKline
Laboratories), who have been active in the ﬁeld of
asthma for the past ﬁfty years, initiated the Asthma
Insights and Reality (AIR) programme in the late
1990s. The AIR programme was designed to collect
information on the different facets of asthma outlined
above through telephone interviews with large
representative samples of the general population.
A standardised questionnaire was developed so that
the survey could be easily replicated in different
countries. The different AIR surveys were performed
as local initiatives in collaboration with national
respiratory associations under the aegis of steering
committees made up of national asthma experts. This
devolved approach allowed the focus of the different
AIR surveys to be tailored to speciﬁc public health
needs in each country, whilst still using a standardised
methodology.
In the United States, the AIR survey (Asthma in
America) was performed in the spring of 1998. This
revealed the extent of the burden of asthma in terms
of high prevalence, signiﬁcant impact on daily life,
poorly controlled disease and inadequate treatment
in the United States. Over the following decade,
the AIR surveys have been rolled out across the
six continents, with the latest to date being the
AIRMAG survey in North Africa, described in this
supplement. All these AIR surveys have in general
highlighted the inadequacy of asthma management in
all participating countries. Nonetheless, it has been
encouraging to see that care standards, at least in
terms of treatment, are somewhat higher in the most
recent surveys compared to the earlier ones, and
that replication of the AIRJ survey in Japan ﬁve years
after the original one could detect improvements
in standards of care and asthma control over the
intervening period.
The information derived from the AIR surveys can help
guide public health policies in the ﬁeld of asthma, by
identifying the most important areas for concern. In
addition, the questionnaires provide a useful tool with
which to benchmark the impact of such policies, as
is illustrated by the Japanese experience. It is to be
hoped that the AIR programme, together with other
such initiatives from the World Health Organization
and the Global Initiative for Asthma, as well as
national and local initiatives, will contribute to a
better quality of life for asthma patients, to less
asthma-related morbidity and mortality and to a more
appropriate use of healthcare resources.
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